Objectives/Hypothesis: To perform a longitudinal description of swallowing function following transoral laser microsurgery (TLM) 6 adjuvant therapy for advanced-stage oropharyngeal cancer (OPC) and identify prognostic factors associated with swallowing performance.
INTRODUCTION
Oropharyngeal (OP) cancer has been increasing in prevalence over the past decade. 1 There are two main treatment options for advanced stage OP cancer: 1) surgical 6 adjuvant treatment or 2) definitive chemoradiotherapy. To avoid open surgical resections, the treatment paradigm for OP cancer shifted toward primary chemoradiotherapy. However, minimally invasive surgical approaches, including transoral laser microsurgery (TLM), have been gaining momentum in Europe and North America, based on excellent oncologic and functional outcomes. 2, 3 Transoral laser microsurgery utilizes intraoperative magnification to visualize tumor-host interfaces and facilitates full resection of malignant tissue while minimizing excision of surrounding normal, functional tissue. It therefore avoids dismantling the musculoskeletal structure of the neck, oral cavity, and pharynx to provide surgical access. The postulate is that patients treated with TLM will retain swallowing function.
However, for survival reasons, patients with advanced OP cancer appear to benefit from adjuvant therapy, 4 which introduces treatment interventions known to acutely 5 and chronically 6 decrease swallowing ability. To date, there are limited data on swallowing function following TLM plus adjuvant therapy for advanced stage OP cancers. The objective of this study was to longitudinally analyze swallowing function, identify risk factors associated with persistently poor swallowing function, and provide data for preoperative counseling.
MATERIALS AND METHODS
Recently we published survival outcomes and preliminary functional data for 84 patients undergoing TLM 6 adjuvant therapy for advanced OP cancer. 2 This current study describes in detail the longitudinal swallowing function of those patients, as well as an additional 34 patients who reached the 2-year postoperative time point since that publication. As previously documented, 2 patients were included in the study who had biopsy proven advanced-stage OP cancer (American Joint Committee on Cancer [AJCC] stages III and IV), had not previously received definitive treatment, and were treated with TLM 6 adjuvant therapy with curative intent at Washington University between June 1996 and June 2008. Patients with a prior history of head and neck aerodigestive tract cancer or evidence of distant metastasis at presentation were excluded from the study. Prior approval from the Human Research Protection Office at Washington University School of Medicine was obtained.
Transoral Laser Microsurgery
Primary tumor site resection was performed using TLM techniques as previously described. 2 In brief, access to the tumor was accomplished using modified laryngoscopes or spatulate retraction devices. Magnification of the operative field was achieved with either an operating microscope or rod telescopes. If needed, the tumor was first debulked using monopolar cauterization. Then using a CO 2 laser, the tumor was transected at multiple points to allow visualization of tumor depth/extension and the tumor/host interface. The tumor was then resected in specimens with at least a 1-cm margin, less when adjacent to vital structures. Frozen sections were utilized as needed to verify complete tumor extirpation. The majority of resection beds were allowed to heal by secondary intent; however, larger defects were reconstructed using local flaps or microvascular free flaps at the surgeons' discretion.
Neck Dissections and Adjuvant Therapy
Neck dissections were performed based on the presence or clinical suspicion of cervical metastases. Levels 2 through 4 were removed in all dissections, with extended dissections performed as needed. Administration and localization of adjuvant therapy was determined at a multidisciplinary tumor board, based on pathologic and intraoperative findings. Adjuvant radiotherapy (RT) was administered as either two-dimensional (2D) or intensity modulated radiation therapy (IMRT).
Postoperative Care
Most patients were allowed to take a liquid diet at postoperative days 1 or 2. Nasogastric tube (NGT) feeds were initiated for those who failed oral feeds or if there was a high clinical suspicion that the patient was at aspiration risk. Nasogastric tubes were removed at subsequent postoperative visits as patients were able to tolerate oral feeds. Criteria for placement of gastrostomy tube (G-tube) were prolonged dysphagia for >2 weeks or loss of >10% of initial body weight.
Evaluation of Swallowing Function
The Functional Outcome Swallowing Scale (FOSS) 7 was used to quantify swallowing function (Table I) . FOSS classifies swallowing function from 0 to 5, with 0 being normal function and 5 representing complete dependence on nonoral feeding. Stages 1 and 2 represent compensated swallow function with only episodic or daily symptoms of dysphagia, and are considered acceptable. Stages 3 to 5 represent decompensated swallowing function with varying degrees of nonoral feeding requirements. Medical records were searched for swallowing data and feeding tube usage throughout the entire treatment course and subsequent follow-up period for each patient. Patients were also directly contacted to provide up-to-date swallowing function data. These data were then translated into FOSS stages. For analyses purposes, each swallowing data point was translated into binary values: 1) ''Good swallowing,'' if FOSS stages from 0-2, or 2) ''Poor swallowing,'' if FOSS stages from 3-5.
Two analyses were performed in this study: 1) longitudinal analyses of swallowing and 2) univariate and multivariate analyses of factors associated with persistently poor swallowing function.
Longitudinal Analyses of Swallowing
To provide a longitudinal overview of swallowing function, FOSS scores were evaluated at or near time points of 1, 3, 6, and 12 months after surgery, then followed by annual assessments up to 5 years. Swallowing function was categorized as good (FOSS 0-2) or poor (FOSS 3-5) for patients who were both living and had available swallowing data at a given time point. The percentage of good swallowing was calculated as the number of patients at a given time point with ''good swallowing'' (FOSS 0-2), divided by all patients with available data for that time point.
Patients were divided into three groups based on their swallowing function during the first 2 years after TLM: 1) Group 1: ''Consistently good'' always had FOSS stages 0-2 during first 2 years; 2) Group 2: ''Recovered good swallowing'' developed dysphagia (FOSS 3-5) during surgery or adjuvant therapy, but then recovered good swallowing (FOSS 0-2) within 2 years after surgery; 3) Group 3: ''Persistently poor'' always had FOSS stages 3-5 during first 2 years.
A fourth subset of patients included ''late-onset swallowing dysfunction,'' which was defined as development of late dysphagia in patients who had maintained good swallowing function during or following cancer treatment. Patients with ''persistently poor swallowing'' were not considered late onset.
Univariate/Multivariate Analyses of Swallowing
Univariate analyses were performed to assess the associations of various factors with patients' swallowing at 2 years following surgery. Two years after surgery was chosen as a time point because there appeared to be a stabilization of swallowing function by 2 years, and it largely avoided confounding factors due to late-onset swallowing dysfunction. Patients were divided into the previously described groups 1-3 for these analyses.
To evaluate the impact of variables on persistently poor swallowing function, group 3 was compared against groups 1 and 2. Significant and clinically relevant variables were then included in a multivariate analysis. Fisher's exact and KruskalWallis tests were utilized as appropriate. All statistical tests were two-tailed and a P value of.05 or less was considered significant. Odds ratios were calculated based on logistic regression models.
Comorbidities at the time of cancer diagnosis were captured using the Adult Comorbidity Evaluation 27 (ACE-27). The ACE-27 is a validated instrument that classifies preexisting comorbidities as either 0 (none), grade 1 (mild), grade 2 (moderate), or grade 3 (severe). A patient's overall status is defined as the highest single ranking ailment, except in the case where two or more grade 2 ailments occur in different organ systems, wherein grade 3 (severe) is designated. [8] [9] [10] Tumor stage (T stage) and nodal stage (N stage) were determined by pathologic assessment. p16 status was determined by immunohistochemical staining as previously described. 2 
RESULTS

Patient Characteristics
One hundred eighteen patients met criteria for analysis in the study. Of these, 115 were treated surgically by the senior author (B.H.H.) and 3 were treated by another surgeon on faculty (see acknowledgments). The mean and median follow-up were 53.9 months and 47.5 months (range 2-138), respectively. 89% of patients had follow-up data through 24 months or greater. Patient characteristics are described in Table II .
Neck Dissection and Adjuvant Therapy
Neck dissections were performed in 116 patients (98%), with 86% undergoing unilateral neck dissections. Only one patient required microvascular free flap reconstruction at the time of the initial surgery. Fifty-five patients received postoperative RT alone and 48 patients received postoperative chemoradiotherapy, for a total of 87% (N ¼ 103) who received adjuvant therapy. The majority of patients undergoing RT received IMRT (87%). Ninety-three patients received RT to the primary site and bilateral necks, 8 patients received RT to the primary site and ipsilateral neck, and 2 received RT to the ipsilateral neck only. The median dosages to both the primary tumor and ipsilateral neck were 6,600 cGy (range ¼ 4,400-7,000). The median dosage to the contralateral neck was 5,600 cGy (range ¼ 3,608-6,600). Six patients received an increased dosage of approximately 7,000 cGy: to the primary site only in four patients, to both the primary site and ipsilateral neck in one patient, and to the ipsilateral neck in one patient. The main chemotherapeutic agent was cisplatin, with two patients receiving carboplatin, two receiving taxol, and two receiving cetuximab.
Longitudinal Analyses of Swallowing
Overview. All 118 patients were included in the longitudinal analyses of swallowing. At 1 month following TLM (with or without neck dissection), 97 patients (82%) had good swallowing. At 3 months postoperatively, which coincides with the administration of adjuvant therapy, the percentage of patients with good swallowing dropped to 55% and rose to 89% by the end of 12 months. At 2, 3, 4, and 5 years after surgery, the percentages of good swallowing were 88%, 88%, 90%, and 93%, respectively (Fig. 1A) .
Consistently good swallowing function. Sixtyfive patients (55%) maintained consistently good swallowing function at all time points during and immediately after their cancer treatment (see Table II for demographics of this group).
Recovered swallowing function. Thirty-eight patients (32%) had poor swallowing function during cancer treatment and then recovered to good swallowing function. Ten patients had poor swallowing immediately following surgery, which persisted through adjuvant therapy before improving, and 28 patients had good swallowing function following surgery and then developed poor swallowing function during adjuvant therapy administration, which eventually recovered. The mean time to recovering good swallow function was 7.2 months following surgery. At 12 months after surgery, 37 of the 38 patients had recovered swallowing function, with 1 outlying patient who recovered good swallowing function at 24 months. When compared to patients who had consistently good swallowing, the recovered group tended to have more advanced tumor stages (T stage 3-4: 32% vs. 14%), more frequent conversions to an open procedure during the initial surgery (11% vs. 0%), greater rate of chemotherapy administration (61% vs. 26%), and more moderate to severe preexisting comorbidities (24% vs. 8%) (Table II) .
Persistently poor swallowing function. Nine patients (8%) had persistently poor swallowing function throughout the length of this study (included in Table  III) . Six of these patients experienced dysphagia immediately following surgery, which never improved; and three patients swallowed well after surgery, then developed dysphagia at 2, 3, and 11 months postoperatively, which never improved. Seven of the 9 patients received adjuvant chemoradiotherapy. Clinically intuitive reasons for persistent dysphagia were multifactorial for most patients, and included: radiation/CRT fibrosis (N ¼ 3), Late-onset swallowing dysfunction. Seven patients (6%) developed late-onset swallowing dysfunction (included in Table III ). The mean time to dysphagia was 34.3 months (range ¼ 18-60). Of these patients, four had good swallowing during their cancer treatment and then developed late-onset dysfunction, and three had poor swallowing during treatment, recovered good swallowing function, then developed late-onset dysfunction. Presumptive reasons for late-onset dysphagia were often multifactorial but included: cancer recurrence (N ¼ 2), development of second head and neck primary malignancy (N ¼ 2), RT induced esophageal stricture (N ¼ 1), diffuse RT fibrosis (N ¼ 3), and Parkinson's disease (N ¼ 1).
Effect of tumor stage and site on longitudinal swallowing function
Dividing patients by tumor site did not reveal difference in swallowing function over time (Fig. 1A) . However, when patients were stratified by T stages, there was a break point in swallowing function between patients with T stages 1-3 and T stage 4 disease (Fig.  1B) . This was more clearly discernable when stratifying patients by tumor site and T stage (Fig. 1C) .
Two-year swallowing outcomes. The percentage of patients with good swallowing at 2 years after surgery was calculated and tabulated by tumor site and tumor stage, to facilitate preoperative counseling of patients regarding posttreatment swallowing expectations (Table  IV) . Overall, at 2 years after surgery, 93% of all patients with T stages 1-3 enjoyed good swallowing, whereas 40% of patients with T stage 4 disease had good swallowing.
Analysis of Factors Affecting Swallow Function
Univariate analysis. Patients were allocated to one of three groups based on their swallowing function during the first 2 years after TLM as described in the Materials and Methods section (characteristics of each group are detailed in Table II ). Six patients who had less than 1 year of swallowing data were excluded (lost to follow-up N ¼ 2; death N ¼ 4), leaving 112 patients for analysis.
• Group 1: Consistently good swallowing (65 patients, 58%), • Group 2: Recovered good swallowing (38 patients, 34%), • Group 3: Persistently poor swallowing (9 patients, 8%). To identify factors associated with persistently poor swallowing function, patients from Group 3 were compared against all other patients using univariate analyses. T stage 4, undergoing bilateral neck dissections, and the administration of chemotherapy were significantly associated with persistently poor swallowing function (Table V) . Neither age at time of surgery, tumor subsite (BOT vs. tonsil), N stage, second-look surgery for revision of margins, nor p16 positivity were associated with persistently poor swallowing function.
The type of RT (2D vs. IMRT) and dosage to each site (primary tumor, ipsilateral neck, and contralateral neck) were also analyzed and found to have no association with swallowing function. Administration of RT to each site was analyzed as an independent variable, as well as RT given to all three sites concurrently, and none were found to be significantly associated with persistently poor swallowing function.
Locoregional recurrence achieved marginal significance (P ¼.051) with persistently poor swallowing. Due to the small numbers of hypoglossal nerve injuries (N ¼ 2) and microvascular free-flap reconstructions (during initial tumor resection) (N ¼ 2), reliable statistical models could not be constructed to assess significance.
Conversion of the initial surgery to an open procedure was not associated with persistently poor swallowing function (all five cases consisted of transhyoid mini-pharyngotomies to facilitate full cancer clearance). However, when comparing patients who never had difficulty swallowing (group 1) to all other patients, conversion to open was significant (P ¼.011). This suggests that converting to an open procedure can delay return of normal swallowing function, but is not associated with permanent swallowing dysfunction.
Preexisting moderate or severe comorbidities (grades 2 or 3) were not associated with persistently poor swallowing function either. However, when comparing patients who never had difficulty swallowing (group 1) to all other patients, having preoperative moderate or severe comorbidities had a significant association (P ¼.028). This suggests that comorbidities may have an effect on the time to return of swallowing function, but are not associated with persistent swallowing dysfunction.
Multivariate analysis. Variables with significance in univariate analyses and of clinical importance were included in a multivariate analysis of persistently poor swallowing function (Table V) . Having T stage 4 disease was significantly associated with persistent swallowing dysfunction at 2 years after surgery, with an odds ratio of 15.20 (P ¼ 0.0023; 95% confidence interval, 2.64-87.46). Undergoing bilateral neck dissections approached signficance in the multivariate analysis (P ¼ 0.055).
DISCUSSION
With the recent rise in incidence of OP cancers, 1 it is incumbent upon otolaryngologists to accurately diagnose, counsel, and treat patients with this disease. Given the unique anatomical location and good prognosis of these cancers in the upper aerodigestive tract, functional outcomes of treatments become nearly as important as survival outcomes. Poor swallowing function is a significant morbidity that affects many aspects of a patient's life, and the presence of a G-tube has been shown to strongly correlate with decreased quality of life. 11 It is therefore preferable for physicians to choose treatments that optimize swallowing function.
Traditionally, advanced OP cancers were treated with large open surgical procedures that dismantled the musculoskeletal infrastructure of the oral cavity and pharynx, resulting in potential disfigurement and swallowing dysfunction. The 1991 Veterans Affairs Laryngeal Cancer Study Group 12 and the Radiation Therapy Oncology Group (RTOG) 91-11 study 13 generated popular interest in the nonsurgical treatment of laryngeal cancer. Such ''organ sparing'' paradigms soon spread to OP tumors in order to limit the aforementioned surgical comorbidities. However, with regard to advanced-stage OP cancer, there have not been any significant, randomized studies comparing surgery and nonsurgical treatments. Thus, it is still not known which treatment provides superior survival and functional outcomes. In addition, the concept of ''organ sparing,'' as it has now been applied to the larynx, has little similarity or application with oropharyngeal structures. Nevertheless, concurrent chemoradiotherapy has now become the main treatment of OP cancers in many centers. To add further complexity, human papilloma virus (HPV)-related OP cancer is increasing in prevalence. This disease entity has been shown to have different tumor biology, treatment responses (to both surgical and nonsurgical treatments), and improved survivorship when compared to non-HPV-related OP cancers.
2,14-16 Thus, primary chemoradiotherapy can not be assumed to be the only ''standard of care'' for OP cancers at this time.
Transoral laser microsurgical approaches to upper aerodigestive tract tumors, such as described by Panje et al. 17 in 1989 in the United States, have been performed for many years. Expansion of these techniques to treat larger laryngeal and OP tumors was popularized in Europe by Wolfgang Steiner and others. 3 Transoral laser microsurgery is an endoscopic approach that utilizes the operating microscope or endoscopes to provide detailed visualization of the tissues. Our prior study and others show that TLM 6 adjuvant therapy for advanced OP cancer provides excellent survival outcomes and local control. 2, 4, 18, 19 It can be postulated that by not dismantling the musculoskeletal architecture, as in TLM, swallowing function should be less affected. However, there is limited data on swallowing function following TLM for advanced stage OP cancers. This study is novel in that it focuses on swallowing function in this particular population, details early and late swallowing function throughout the whole treatment process, and has longterm follow-up. Swallowing function at 2 years after surgery was chosen as the primary outcome for this study. Even though swallowing function changes considerably during treatment of OP cancers, it is the long-term swallowing function that is most important clinically and to patients.
We show that, in general, resection of oropharyngeal tumors with TLM, neck dissections 6 adjuvant therapy results in good swallowing function. Specifically, patients' swallowing function was minimally affected by surgical resection of the primary tumor and neck dissections, as evidenced by 82% of patients with good swallowing 1 month following surgery. Rather, it was the administration of adjuvant therapy that most severely affected swallowing function, as shown by a drop in good swallowing function to 55% at 3 months. However, most patients were able to recover and at 1 year 89% of patients had good swallowing function.
The combined therapy of TLM plus adjuvant therapy is tolerated modestly well, as evidenced by 55% of patients never experiencing swallowing dysfunction. An additional 32% of patients experienced a temporary episode of poor swallowing, requiring feeding tube supplementation, but then returned to normal swallowing at a median of 7.2 months. Only 8% of patients were left with poor swallowing function at 2 years of followup.
The pathogenesis of dysphagia and/or G-tube dependency following treatment of OP cancers is multifactorial.
Deep resection of the BOT may cause denervation, loss of tongue volume and potential difficulty propelling food boluses beyond the oropharynx. Radiation therapy causes acute complications that affect oral intake, such as mucositis, edema, xerostomia, altered taste, and contracture of denuded/inflamed mucosal surfaces. Delayed and progressive complications like pharyngeal or esophageal strictures, pharyngeal muscle dysfunction, diffuse fibrosis, mucosal atrophy/drying, thickened secretions and trismus also contribute to poor swallowing function. Radiation therapy also causes obliteration of the microvascularity of tissues, which predisposes to radionecrosis (i.e., of mandible or soft tissue). Extensive parapharyngeal space radionecrosis of one patient in our study resulted in thrombosis of the internal carotid artery and stroke, as well as significant tissue destruction necessitating free flap reconstruction. These effects are markedly accentuated with the addition of chemotherapy, resulting in more extensive side effects to surrounding normal tissue. 20 We have previously shown significant progressive escalation of swallowing dysfunction between no adjuvant therapy, radiation alone, and chemoradiation following TLM. 4 In multivariate analysis, T stage 4 was found to be significantly associated with persistently poor swallowing at 2 years after surgery (odds ratio of 15.20 when compared to T stages 1-3). This finding is clinically intuitive and is most likely due to resection of greater volume with higher stage tumors. Boosting RT to the primary site of these larger tumors and adding concurrent chemotherapy also plays a role in swallowing dysfunction. Tumor site (BOT vs. tonsil) however, was not associated with persistently poor swallowing.
Undergoing bilateral neck dissections approached but did not achieve significance in the multivariate analysis (P ¼ 0.055). This is also clinically intuitive and might reach significance with larger numbers. This finding also underscores the judicious use of bilateral neck dissections in the treatment of OP cancers, so as not to detrimentally affect swallowing function.
Interestingly, age at the time of surgery was not associated with permanent swallowing dysfunction. The oldest patient in this series was an 81-year-old man who underwent TLM for a T stage 3 BOT cancer and maintained good swallowing postoperatively. We have found that older patients tend to tolerate TLM better than chemoradiotherapy; thus, in select elderly patients, surgery as a unimodality treatment should be considered.
Returning to the operating room for endoscopic reresection to obtain negative margins was not associated with persistently poor swallowing outcomes. Conversion of the initial surgery to an open procedure (transhyoid mini-pharyngotomies in this study) to obtain negative margins was associated with a delay in return to normal swallowing function. However, conversion to an open procedure was not associated with persistent swallowing dysfunction. Thus, surgeons can be reassured that expanding the surgical resection to obtain negative margins, either by reresection or pharyngotomy, is not necessarily associated with persistently poor swallowing function for the patient.
Because most patients received adjuvant RT (87%) in this study, and the range of radiation dosages was very narrow, we did not detect an effect on swallowing by either the dosage of RT or locations of RT administered (primary site, ipsilateral neck, contralateral neck). Interestingly, there was also no difference in swallowing function between patients who received 2D or IMRT.
Chemotherapy acts synergistically with radiotherapy to enhance cancer cell death, but also accentuates the negative effects of radiotherapy to the surrounding normal tissue. 20 This detrimental effect was observed in our study as 78% of patients with persistently poor swallowing received adjuvant chemotherapy. Chemotherapy was significantly associated with poor swallowing function in the univariate analysis (P ¼ .034), and may reach multivariate significance with a larger sample size.
Adjuvant RT has been shown to improve survival following TLM, 4 and in this study the majority of patients (87%) received adjuvant RT. One may argue that primary surgical resection does not minimize treatment morbidity if most patients still require adjuvant RT or chemoradiotherapy. However, the overall dosages of RT for adjuvant treatment are less than that for definitive primary treatment. Most primary chemoradiotherapy protocols apply 7,000 cGy to the primary site and involved lymph nodes, 13, 21, 22 whereas in this study the median dose for adjuvant RT to the primary site and ipsilateral neck were 6,600 cGy and 5,600 cGy to contralateral neck. This may seem to be a nominal difference, but the probability of normal tissue complications with increasing RT dose is sigmoidal rather than linear. 23, 32 Thus, decreasing overall RT dosages to adjuvant levels theoretically leads to lower risk of normal tissue complications. We are currently investigating lower doses and more precisely targeted fields of radiotherapy (unilateral rather than bilateral neck fields) than were used in this series, which should decrease the swallowing decrements observed during the adjuvant phase of treatment. Furthermore, we have preliminary evidence of no association of survival benefit from adjuvant chemotherapy in p16þ patients (2, 4) suggesting a reduced role for this modality in future.
Comparison of swallowing between primary surgery with adjuvant therapy and primary chemoradiotherapy is difficult due to conflicting reports. Tschudi et al. 24 showed improved quality of life with surgery, Gillespie et al. 25 suggest patients undergoing primary CRT have a better swallowing quality of life, whereas Mowry et al. 26 showed no difference between these groups. Published G-tube dependency rates following TLM 6 adjuvant therapy for OP cancers range from 0% to 10%. 19, 27, 28 This is in marked contrast to G-tube dependency rates of 15% to 25% following primary radiotherapy, 29, 30 and 18.1% to 51%, following primary chemoradiotherapy. 6, 29, 31 Complicating these studies is a lack of conformity and detail regarding definitions and timing of reported G-tube dependency in the literature, since we show in this study that swallowing is a very dynamic process throughout the treatment and recovery of OP cancers. Therefore longitudinal, prospective data collection for swallowing in surgical and nonsurgical cohorts of advanced stage oropharyngeal cancers should be performed to clarify this issue.
Preoperative counseling is important to enable patients to make educated treatment decisions. Our findings show how preoperative T stage can be used to counsel patients regarding expected swallowing outcomes (Table  IV) . Based on our institution's experience, patients with OP cancers of T-stages 1 through 3 who undergo TLM þ/À adjuvant therapy have a high probability of good swallowing function at 2 years after surgery (average 93%, range 71-100%). Patients with T stage 4 tumors, either BOT or tonsil, have the lowest probability of good swallowing at 2 years (43% and 33%, respectively). However, patients with such advanced tumors are likely to have poor swallowing function regardless of the treatment modality employed (surgical or non-surgical). Likewise, in terms of preoperative counseling and planning, we found that moderate or severe preexisting comorbidities may predispose a patient to a delayed return in swallowing following cancer treatment. However, most patients with these comorbidities had return of good swallowing function, and there was no association with persistently poor swallowing.
Late-onset dysphagia is a significant concern, for which practitioners must be watchful. Chemoradiotherapy has been shown to produce significant late toxicities 2-3 years after treatment. 6 In our study, 7 patients (6% of total) developed late-onset swallowing dysfunction, with a median time to onset of 34.3 months (range ¼ 18-60 months). The main causes for this dysphagia were cancer related (N ¼ 3, either primary recurrence or second primary cancer) and late RT/CRT effects (N ¼ 4, diffuse radiation fibrosis or esophageal strictures).
The Functional Outcome Swallowing Scale or FOSS was used as the primary measurement instrument in this study. The FOSS has been used extensively at our institution and others because it is simple to use and has been shown to have high interrater reliability. 7 We find FOSS measurements to be more sensitive to detect swallow function than using the presence or absence of G-tubes alone. For example, patients' swallowing dysfunction is often preceded by NGT feeding for a period of time. This early dysphagia is not reported if only the presence of G-tubes is used as a measurement of dysphagia. Likewise, some patients maintain a G-tube for many months after return of good swallowing function before the feeding tube is finally removed. Using removal of G-tubes would therefore not be an accurate measurement of return to function.
As with any study, there are limitations that must be addressed. First, this is a retrospective analysis of swallowing function, which has its inherent biases. Also, because most patients received adjuvant therapy, it is difficult to separate the direct effects of TLM or chemo/ radiotherapy on final swallowing function. A patient reported swallowing scale, FOSS, was utilized rather than objective swallowing studies. However, for the intent of assessing the longitudinal swallowing patterns of patients, multiple radiographic swallowing tests would have been overly expensive and impractical.
Performance status, patient motivation and gastroesophageal reflux also have an impact on swallowing function, and were not assessed in this study. Future research will hopefully elucidate such factors.
CONCLUSIONS
In this study we demonstrate that TLM 6 adjuvant therapy for advanced stage OP carcinoma results in very good, long-term swallowing function. Approximately 90% of patients enjoy good swallowing at one year after surgery. T1, T2 and T3 cases of both base of tongue and tonsil reliably recovered swallowing, usually by one year. T4 cases may have prolonged recovery, or persistently poor function.
